Update on the Aldosterone Resolution Score and Lateralization in Patients with Primary Aldosteronism

Article information

Endocrinol Metab. 2018;33(3):352-354
Publication date (electronic) : 2018 September 18
doi : https://doi.org/10.3803/EnM.2018.33.3.352
Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
Corresponding author: Eun-Hee Cho. Department of Internal Medicine, Kangwon National University School of Medicine, 1 Gangwondaehak-gil, Chuncheon 24341, Korea. Tel: +82-33-258-9167, Fax: +82-33-258-2455, ehcho@kangwon.ac.kr
Received 2018 August 20; Accepted 2018 August 27.

Primary aldosteronism (PA), first described by Jerome W. Conn in 1955 [1], is characterized by excessive, autonomous aldosterone production relative to suppressed plasma renin. PA is currently an important curable cause of secondary hypertension, and has been increasingly diagnosed in patients with hypertension because of emerging interest in PA and advances in knowledge of this condition. Patients with PA have been found to be at a higher risk of cardiovascular events and target organ damage in the heart and kidney than patients with essential hypertension [234], suggesting that early diagnosis and appropriate clinical management are important. PA is usually caused by a unilateral aldosterone-producing adenoma (APA) or unilateral or bilateral adrenal hyperplasia, although in rare cases, it may be caused by adrenal carcinoma or inherited familial hyperaldosteronism. PA is specifically treated by surgery (unilateral adrenalectomy) or medical treatment with a mineralocorticoid receptor antagonist.

After unilateral adrenalectomy for APA, hypertension outcomes and the factors associated with complete resolution of hypertension are variable. Zarnegar et al. [5] first developed the simple aldosterone resolution score (ARS) to predict the complete resolution of hypertension after adrenalectomy with unilateral APA, based on four routinely available initial clinical variables (≤2 antihypertensive medications, body mass index [BMI] ≤25 kg/m2, duration of hypertension ≤6 years, and female sex) that predicted hypertension resolution. In the same study, taking ≤2 antihypertensive medications was found to be the strongest independent predictor of resolution of hypertension, with an odds ratio of roughly twice that of other variables. In another study of 91 Japanese patients who underwent unilateral adrenalectomy for APA, taking fewer than three antihypertensive medications, a duration of hypertension ≤6 years, and female sex were demonstrated to be predictors of complete resolution of hypertension, confirming the factors included in the ARS, except for BMI [6]. However, in a recent study of 310 French patients with APA, of the variables included in the ARS, only a BMI ≤25 kg/m2 and taking ≤2 antihypertensive medications were significant predictors [7].

A study by Loh et al. [8] demonstrated that only a short duration of hypertension (≤6 years) and an ARS of 3 to 5 were associated with resolution of hypertension after adrenalectomy in 40 patients with PA in Singapore, in contrast to the results of previous studies of ARS [56]. In 376 Chinese patients with APA, only a duration of hypertension of ≥6 years and a level of plasma aldosterone ≥35 ng/dL were significant independent negative predictors for complete hypertension cure [9]. In an international cohort study of patients with PA [10], unilateral adrenalectomy achieved complete clinical success in 37% of 705 patients, and complete biochemical success (correction of hypokalemia and normalization of the aldosterone-to-renin ratio) was found in 94% (range, 83% to 100%) of 699 patients. In that study, patients with younger age and female sex received greater surgical clinical benefits from adrenalectomy [10]. Hypertension with PA is dependent not only on excessive aldosterone secretion, but also on existing essential hypertension and vascular or renal damage induced by a long duration of antecedent aldosterone-induced hypertension.

Since the updated recommendation of the Endocrine Society practice guideline on PA was released in 2016 [4], accumulating evidence has advanced our knowledge of the genetics, case detection, screening, diagnosis, subtype differentiation, and treatment of PA. Lateralization of the source of excessive aldosterone secretion between unilateral and bilateral disease is critical in the management of PA. Adrenal venous sampling (AVS) is regarded as the gold-standard method for differentiating between unilateral and bilateral disease in patients with PA [4]. However, AVS is considered to be a difficult procedure because of the technical difficulty of cannulating the right adrenal vein. Recently, there have been advances in AVS cannulation with the introduction of rapid on-site measurements of adrenal vein cortisol concentrations [11] and C-arm computed tomography-guided cannulation [12]. New immunoassay measurements of hybrid steroids, such as 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol, have recently shown improved sensitivity and specificity, suggesting their potential use as surrogate markers for the diagnosis and lateralization of unilateral PA in combination with adrenal imaging [1314].

11C-metomidate positron emission tomography tracers were developed as an alternative to AVS because metomidate binds to steroidogenic enzymes, including CYP11B, and enzymes involved in the biosynthesis of aldosterone and cortisol, suggesting its suitability in adrenocortical functional imaging for the lateralization of APA [15]. The study by Loh et al. [8] suggested that the contralateral ratio (CR) might be a useful alternative to AVS for considering surgery in the setting of unilateral cannulation of the adrenal vein, but their study acknowledged that many unanswered questions remained to be resolved and that prospective clinical trials must be conducted to determine appropriate cut-offs of the CR and the efficacy of the CR relative to AVS.

For future research, a prospective multi-center large-scale design with standardized blood pressure assessments in the general population is required to develop and verify a novel and effective prediction model of the outcomes of adrenalectomy, including the resolution of hypertension and the incidence of cardiovascular events.


CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.


1. Conn JW. Presidential address. J Lab Clin Med 1955;45:3–17. 13233623.
2. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243–1248. 15837256.
3. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27:1039–1045. 8621194.
4. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016;101:1889–1916. 26934393.
5. Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, Farley DR, et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 2008;247:511–518. 18376197.
6. Utsumi T, Kawamura K, Imamoto T, Kamiya N, Komiya A, Suzuki S, et al. High predictive accuracy of Aldosteronoma Resolution Score in Japanese patients with aldosterone-producing adenoma. Surgery 2012;151:437–443. 22000827.
7. Pasquier L, Kirouani M, Fanget F, Nomine C, Caillard C, Arnault V, et al. Assessment of the aldosteronona resolution score as a predictive resolution score of hypertension after adrenalectomy for aldosteronoma in French patients. Langenbecks Arch Surg 2017;402:309–314. 28111697.
8. Loh WJ, Lim DST, Loh LM, Kek PC. Factors associated with resolution of hypertension after adrenalectomy in patients with primary aldosteronism. Endocrinol Metab (Seoul) 2018;33:355–363.
9. Zhang X, Zhu Z, Xu T, Shen Z. Factors affecting complete hypertension cure after adrenalectomy for aldosterone-producing adenoma: outcomes in a large series. Urol Int 2013;90:430–434. 23466491.
10. Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017;5:689–699. 28576687.
11. Reardon MA, Angle JF, Abi-Jaoudeh N, Bruns DE, Haverstick DM, Matsumoto AH, et al. Intraprocedural cortisol levels in the evaluation of proper catheter placement in adrenal venous sampling. J Vasc Interv Radiol 2011;22:1575–1580. 21700477.
12. Park CH, Hong N, Han K, Kang SW, Lee CR, Park S, et al. C-arm computed tomography-assisted adrenal venous sampling improved right adrenal vein cannulation and sampling quality in primary aldosteronism. Endocrinol Metab (Seoul) 2018;33:236–244. 29766680.
13. Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, Mengozzi G, et al. 18-Hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab 2012;97:881–889. 22238407.
14. Nakamura Y, Satoh F, Morimoto R, Kudo M, Takase K, Gomez-Sanchez CE, et al. 18-Oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism. J Clin Endocrinol Metab 2011;96:E1272–E1278. 21593107.
15. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab 2012;97:100–109. 22112805.

Article information Continued